Cannabielsoin (CBE), a CBD Oxidation Product, Is a Biased CB Agonist

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2024 Jul 27

PMID 39062125

Authors

Mehdi Haghdoost

Scott Young

Matthew Roberts

Caitlyn Krebs

Marcel O Bonn-Miller

Affiliations

Soon will be listed here.

Abstract

Cannabielsoin (CBE) is primarily recognized as an oxidation byproduct of cannabidiol (CBD) and a minor mammalian metabolite of CBD. The pharmacological interactions between CBE and cannabinoid receptors remain largely unexplored, particularly with respect to cannabinoid receptor type 1 (CB). The present study aimed to elucidate the interaction dynamics of CBE in relation to CB by employing cyclic adenosine monophosphate (cAMP) and β-arrestin assays to assess its role as an agonist, antagonist, and positive allosteric modulator (PAM). To our knowledge, this is the first publication to investigate CBE's receptor activity in vitro. Our findings reveal that -CBE acts as an agonist to CB with EC = 1.23 µg/mL (3.7 µM) in the cAMP assay. No agonist activity was observed in the β-arrestin assay in concentrations up to 12 µM, suggesting a noteworthy affinity towards G-protein activation and the cAMP signaling pathway. Furthermore, in silico molecular docking simulations were conducted to provide a structural basis for the interaction between CBE and CB, offering insights into the molecular determinants of its receptor affinity and functional selectivity.

References

Ryalls B, Patel M, Sparkes E, Banister S, Finlay D, Glass M . Investigating selectivity and bias for G protein subtypes and β-arrestins by synthetic cannabinoid receptor agonists at the cannabinoid CB receptor. Biochem Pharmacol. 2024; 222:116052. DOI: 10.1016/j.bcp.2024.116052. View

Sassone-Corsi P . The cyclic AMP pathway. Cold Spring Harb Perspect Biol. 2012; 4(12). PMC: 3504441. DOI: 10.1101/cshperspect.a011148. View

Hampson A, Grimaldi M, Axelrod J, Wink D . Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A. 1998; 95(14):8268-73. PMC: 20965. DOI: 10.1073/pnas.95.14.8268. View

Monroe A, Gordon W, Wood J, Martin G, Morgan J, Williamson R . Structural revision of a Wnt/β-catenin modulator and confirmation of cannabielsoin constitution and configuration. Chem Commun (Camb). 2021; 57(46):5658-5661. DOI: 10.1039/d1cc01971f. View

Nalli Y, Dar M, Bano N, Rasool J, Sarkar A, Banday J . Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain. Bioorg Med Chem Lett. 2019; 29(9):1043-1046. DOI: 10.1016/j.bmcl.2019.03.013. View

Silmore L, Willmer A, Capparelli E, Rosania G . Food effects on the formulation, dosing, and administration of cannabidiol (CBD) in humans: A systematic review of clinical studies. Pharmacotherapy. 2021; 41(4):405-420. PMC: 8485703. DOI: 10.1002/phar.2512. View

Go M, Zhu T, Lim K, Hartono Y, Xue B, Fan H . Cannabinoid Biosynthesis Using Noncanonical Cannabinoid Synthases. Int J Mol Sci. 2023; 24(2). PMC: 9862763. DOI: 10.3390/ijms24021259. View

Tian X, Kang D, Benovic J . β-arrestins and G protein-coupled receptor trafficking. Handb Exp Pharmacol. 2013; 219:173-86. PMC: 4513654. DOI: 10.1007/978-3-642-41199-1_9. View

Haghdoost M, Lopez de Los Santos Y, Brunstetter M, Ferretti M, Roberts M, Bonn-Miller M . Using In Silico Molecular Docking to Explain Differences in Receptor Binding Behavior of HHC and THCV Isomers: Revealing New Binding Modes. Pharmaceuticals (Basel). 2024; 17(5). PMC: 11125018. DOI: 10.3390/ph17050637. View

10.

Radwan M, Chandra S, Gul S, ElSohly M . Cannabinoids, Phenolics, Terpenes and Alkaloids of . Molecules. 2021; 26(9). PMC: 8125862. DOI: 10.3390/molecules26092774. View

11.

Eberhardt J, Santos-Martins D, Tillack A, Forli S . AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings. J Chem Inf Model. 2021; 61(8):3891-3898. PMC: 10683950. DOI: 10.1021/acs.jcim.1c00203. View

12.

Zhu X, Finlay D, Glass M, Duffull S . Evaluation of the profiles of CB cannabinoid receptor signalling bias using joint kinetic modelling. Br J Pharmacol. 2020; 177(15):3449-3463. PMC: 7369624. DOI: 10.1111/bph.15066. View

13.

Salehi A, Puchalski K, Shokoohinia Y, Zolfaghari B, Asgary S . Differentiating Cannabis Products: Drugs, Food, and Supplements. Front Pharmacol. 2022; 13:906038. PMC: 9271575. DOI: 10.3389/fphar.2022.906038. View

14.

Gerard C, Mollereau C, Vassart G, Parmentier M . Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J. 1991; 279 ( Pt 1):129-34. PMC: 1151556. DOI: 10.1042/bj2790129. View

15.

Pertwee R . The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2007; 153(2):199-215. PMC: 2219532. DOI: 10.1038/sj.bjp.0707442. View

16.

Thomson B, Hanna S, Schwarzenberg A, Kiani P, Bizzotto D, Kennepohl P . CBD hydroxyquinone photo-isomerises to a highly reactive intermediate. Sci Rep. 2023; 13(1):6967. PMC: 10147596. DOI: 10.1038/s41598-023-33815-7. View

17.

Mackie K . Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol. 2006; 46:101-22. DOI: 10.1146/annurev.pharmtox.46.120604.141254. View

18.

Kumar K, Robertson M, Thadhani E, Wang H, Suomivuori C, Powers A . Structural basis for activation of CB1 by an endocannabinoid analog. Nat Commun. 2023; 14(1):2672. PMC: 10169858. DOI: 10.1038/s41467-023-37864-4. View

19.

Shapovalov M, Dunbrack Jr R . A smoothed backbone-dependent rotamer library for proteins derived from adaptive kernel density estimates and regressions. Structure. 2011; 19(6):844-58. PMC: 3118414. DOI: 10.1016/j.str.2011.03.019. View

20.

Ujvary I, Hanus L . Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in Therapy. Cannabis Cannabinoid Res. 2017; 1(1):90-101. PMC: 5576600. DOI: 10.1089/can.2015.0012. View